Santen Pharmaceutical Co., Ltd.
Prognozy (mln)
| Okres |
2024-03-31 |
2025-03-31 |
2026-03-31 |
2027-03-31 |
2028-03-31 |
2029-03-31 |
2030-03-31 |
| Przychód (średnia) |
302,306.67 |
298,626.25 |
295,480.42 |
305,105.40 |
317,217.53 |
309,450.00 |
321,300.00 |
| Przychód Δ r/r |
0.00% |
-1.22% |
-1.05% |
3.26% |
3.97% |
-2.45% |
3.83% |
| Przychód (min) |
296,646.76 |
284,803.22 |
280,500.02 |
260,899.96 |
317,217.52 |
278,954.68 |
289,636.90 |
| Przychód (max) |
304,917.40 |
304,103.44 |
308,000.02 |
325,999.95 |
317,217.54 |
326,666.54 |
339,175.83 |
| EBITDA (średnia) |
47,923.69 |
47,340.25 |
46,841.55 |
48,367.36 |
50,287.46 |
49,056.10 |
50,934.64 |
| EBIT (średnia) |
28,715.30 |
28,365.70 |
28,066.89 |
28,981.14 |
30,131.64 |
29,393.82 |
30,519.42 |
| EBIT % |
9.50% |
9.50% |
9.50% |
9.50% |
9.50% |
9.50% |
9.50% |
| Zysk netto (średni) |
27,714.00 |
36,247.00 |
34,180.10 |
38,400.00 |
42,300.00 |
47,103.78 |
51,370.05 |
| Zysk netto % |
9.17% |
12.14% |
11.57% |
12.59% |
13.33% |
15.22% |
15.99% |
| EPS (średnia) |
87.31 |
99.17 |
102.58 |
116.48 |
128.25 |
134.70 |
146.90 |
| Liczba analityków (Przychody) |
8 |
8 |
10 |
9 |
9 |
4 |
4 |
| Liczba analityków (EPS) |
8 |
9 |
10 |
9 |
9 |
3 |
3 |
| symbol |
4536.T |
4536.T |
4536.T |
4536.T |
4536.T |
4536.T |
4536.T |